Alpha Cognition Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Alpha Cognition Inc. (ACOG) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $945.14K, a 293.87% increase year-over-year.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.67M, a 2952.33% decline year-over-year.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $2.43M, a 249.46% increase year-over-year.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $3.72M, a 642.22% increase year-over-year.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $6.52M, a 523.90% increase from fiscal 2024.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.05M.
- Alpha Cognition Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$1.45M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $945.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.72M 10-Q · filed 2026-08-13 | -$291.02K derived: sum of 3 quarters · filed 2026-08-13 | $3.43M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$3.67M 10-Q · filed 2026-05-14 | -$1.24M derived: sum of 2 quarters · filed 2026-05-14 | $2.49M derived: sum of 3 quarters · filed 2026-05-14 | $2.72M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $6.15M derived: sum of 2 quarters · filed 2026-03-31 | $6.39M derived: sum of 3 quarters · filed 2026-08-13 | $6.52M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $3.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.96M derived: sum of 2 quarters · filed 2026-08-13 | $4.09M 10-Q · filed 2025-11-13 | $4.79M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $239.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $368.53K 10-Q · filed 2026-08-13 | $1.06M derived: sum of 3 quarters · filed 2026-08-13 | $1.57M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $128.57K 10-Q · filed 2026-05-14 | $824.26K derived: sum of 2 quarters · filed 2026-05-14 | $1.33M derived: sum of 3 quarters · filed 2026-05-14 | $1.68M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $695.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.20M derived: sum of 2 quarters · filed 2026-03-31 | $1.55M derived: sum of 3 quarters · filed 2026-03-31 | $1.05M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $501.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $853.22K derived: sum of 2 quarters · filed 2025-11-13 | $349.48K 10-Q · filed 2025-11-13 | $349.48K 10-Q · filed 2024-11-14 | $210.94K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $351.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$151.88K 10-Q · filed 2025-08-14 | -$290.42K derived: sum of 3 quarters · filed 2025-08-14 | $229.39K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$503.74K 10-Q · filed 2025-05-15 | -$642.28K derived: sum of 2 quarters · filed 2025-05-15 | -$122.47K derived: sum of 3 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$138.53K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $381.27K derived: sum of 2 quarters · filed 2025-03-31 | -$1.45M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $519.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.31M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$1.83M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |